Literature DB >> 20038751

Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.

Curt D Sigmund1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20038751      PMCID： PMC2819308          DOI： 10.1161/HYPERTENSIONAHA.109.144170

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  72 in total

1.  Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells.

Authors:  K Takeda; T Ichiki; T Tokunou; Y Funakoshi; N Iino; K Hirano; H Kanaide; A Takeshita
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

2.  Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

Authors:  S Füllert; F Schneider; E Haak; H Rau; K Badenhoop; G Lübben; K-H Usadel; T Konrad
Journal:  J Clin Endocrinol Metab       Date:  2002-12       Impact factor: 5.958

3.  Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells.

Authors:  S Wakino; U Kintscher; S Kim; F Yin; W A Hsueh; R E Law
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

4.  Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells.

Authors:  N Marx; F Mach; A Sauty; J H Leung; M N Sarafi; R M Ransohoff; P Libby; J Plutzky; A D Luster
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

5.  Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

Authors:  R E Law; S Goetze; X P Xi; S Jackson; Y Kawano; L Demer; M C Fishbein; W P Meehan; W A Hsueh
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

6.  The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells.

Authors:  I Inoue; S Goto; T Matsunaga; T Nakajima; T Awata; S Hokari; T Komoda; S Katayama
Journal:  Metabolism       Date:  2001-01       Impact factor: 8.694

7.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

8.  Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells.

Authors:  David S Calnek; Louis Mazzella; Susanne Roser; Jesse Roman; C Michael Hart
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

9.  Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.

Authors:  Marc Iglarz; Rhian M Touyz; Farhad Amiri; Marie-France Lavoie; Quy N Diep; Ernesto L Schiffrin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-01       Impact factor: 8.311

10.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Authors:  David B Savage; Garry D Tan; Carlo L Acerini; Susan A Jebb; Maura Agostini; Mark Gurnell; Rachel L Williams; A Margot Umpleby; E Louise Thomas; Jimmy D Bell; Adrian K Dixon; Fidelma Dunne; Romina Boiani; Saverio Cinti; Antonio Vidal-Puig; Fredrik Karpe; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  Diabetes       Date:  2003-04       Impact factor: 9.461
View more
  25 in total

1.  Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice.

Authors:  Avani A Pendse; Lance A Johnson; Hyung-Suk Kim; Marcus McNair; C Taylor Nipp; Carolyn Wilhelm; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-26       Impact factor: 8.311

Review 2.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 3.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

Review 4.  Hyperhomocysteinemia impairs regional blood flow: involvements of endothelial and neuronal nitric oxide.

Authors:  Noboru Toda; Tomio Okamura
Journal:  Pflugers Arch       Date:  2016-07-14       Impact factor: 3.657

Review 5.  PPARγ and retinol binding protein 7 form a regulatory hub promoting antioxidant properties of the endothelium.

Authors:  Addison W Woll; Frederick W Quelle; Curt D Sigmund
Journal:  Physiol Genomics       Date:  2017-09-15       Impact factor: 3.107

Review 6.  Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.

Authors:  Marko Stojanović; Milica Prostran; Miroslav Radenković
Journal:  Eur J Clin Pharmacol       Date:  2015-12-22       Impact factor: 2.953

Review 7.  Endothelial PPARγ Is Crucial for Averting Age-Related Vascular Dysfunction by Stalling Oxidative Stress and ROCK.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Md Jakaria; Abdullah Al Mamun; Kamal Niaz; Md Shah Amran; George E Barreto; Ghulam Md Ashraf
Journal:  Neurotox Res       Date:  2019-05-04       Impact factor: 3.911

Review 8.  The adaptation of the cerebral circulation to pregnancy: mechanisms and consequences.

Authors:  Marilyn J Cipolla
Journal:  J Cereb Blood Flow Metab       Date:  2013-01-16       Impact factor: 6.200

9.  Interference With Endothelial PPAR (Peroxisome Proliferator-Activated Receptor)-γ Causes Accelerated Cerebral Vascular Dysfunction in Response to Endogenous Renin-Angiotensin System Activation.

Authors:  Anand R Nair; Larry N Agbor; Masashi Mukohda; Xuebo Liu; Chunyan Hu; Jing Wu; Curt D Sigmund
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

10.  Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase.

Authors:  Christopher J Pelham; Pimonrat Ketsawatsomkron; Séverine Groh; Justin L Grobe; Willem J de Lange; Stella-Rita C Ibeawuchi; Henry L Keen; Eric T Weatherford; Frank M Faraci; Curt D Sigmund
Journal:  Cell Metab       Date:  2012-10-03       Impact factor: 27.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.